<DOC> 
<DOCNO>1080515_business_story_9271826.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Glaxo inks pact with Daiichi
                                                                                                                                                                                                                                                                                                                                                                       Glaxo inks pact with Daiichi
          OUR SPECIAL CORRESPONDENT                              
	Mumbai, May 14: GlaxoSmithKline (GSK) Pharma has entered into a co-promotion agreement with Daiichi Sankyo India Pharma Ltd to bring the latters anti-hypertensive drug Olmesartan Medoxomil and its combination products in India.        
	Daiichi Sankyo India is a subsidiary of Daiichi Sankyo Company Ltd, the Japanese pharmaceutical company based in Tokyo.         
	Olmesartan is an original research product of Daiichi Sankyo and it is a $2-billion drug. The anti-hypertensive market is seen to have a huge potential in India. Sales of the drug are expected to start in June this year.        
	This is the second such in-licensing deal that GSK has struck with a Japanese company this month.         
	Earlier, it sealed a deal to sell Astellas Pharma Incs injectible anti-fungal agent Micafungin in India.         
	Hasit Joshipura, managing director of GSK India, said, This agreement comes close on the heels of our in-licensing agreement for Micafungin last week. Our strategy, as laid out at the beginning of the year, for in-licensing products in specific high growth therapeutic areas is being rolled out and is well on track.                                                                                                                                      
</TEXT> 
</DOC>